Achieve Safe & Targeted In Vivo Delivery of Payloads with Clarity in Regulations & Appropriate Models to Advance the Next Frontier of In Vivo Editing from Research to Clinic

July 9-11, 2024 | Boston, MA

Register
See Full Agenda
Partner

Save up to $850 - Offer Ends this Friday, April 19!

Day
Hour
Minute
Second

Welcome to the 3rd In Vivo Cell Engineering & Gene Editing Summit!

As promising pre-clinical and proof of concept results continue to emerge, the pivotal shift from the β€˜dream’ of in vivo cell engineering and gene editing is rapidly becoming a reality as numerous companies push towards the clinic. Uniting key thought-leading experts, the 3rd In Vivo Cell Engineering & Gene Editing Summit will be a uniquely positioned, must-attend gathering, delving into all facets of development to spearhead in vivo as the frontier of cell and gene therapies.

Crafted in collaboration with industry titans such as Capstan Therapeutics, Editas Medicine, NanoCell Therapeutics, Carisma Therapeutics, Mustang Bio, iECURE, and many others, our newly curated agenda for 2024 promises unparalleled insights:

Join us this July to glean invaluable knowledge from our world-class speaker faculty, offering an exclusive dive into how experts plan to stay ahead of the curve and shape the future of cell and gene therapy in the years ahead.

3rd In Vivo Cell Engineering & Gene Editing Summit - Full Agenda
See Full Agenda

"In vivo genetic medicines are the future, so having a forum for leaders in the field to explore ways to navigate development to meet the needs of patients is very exciting"
Nicolas Boyle, Chief Executive Officer, Abintus Bio

Key Highlights

3rd In Vivo Cell Engineering & Gene Editing Summit

Exploring data-driven case studies to outline decision making when selecting viral versus non-viral vectorsΒ 

3rd In Vivo Cell Engineering & Gene Editing Summit

Clarifying regulatory expectations for this novel therapeutic approachΒ to map out the future of your pipeline

3rd In Vivo Cell Engineering & Gene Editing Summit

Benchmarking appropriate preclinical models to support translationΒ to gain valuable data needed by regulatory bodies

3rd In Vivo Cell Engineering & Gene Editing Summit

Outlining the considerations when scaling up towards the clinic to equip you with the tools to tackle bottlenecks

3rd In Vivo Cell Engineering & Gene Editing Summit

Emphasizing target specificity and the mitigation of off-site toxicities to ensure safety is front of mind in development

 

Download the Full Agenda for More Information on:

        • 15+ In Vivo Expert Speakers
        • 2 Interactive Deep-Dive Workshops
        • 8+ Hours of Industry Networking
        • & Much More!

       

       

 

 

See Full Agenda
3rd In Vivo Cell Engineering & Gene Editing Summit - Full Agenda

World-Class Speaker Faculty Includes

3rd In Vivo Cell Engineering & Gene Editing Summit - Expert Speaker - Adrian Bot

Adrian Bot

Chief Scientific Officer

Capstan Therapeutics

3rd In Vivo Cell Engineering & Gene Editing Summit - Expert Speaker - Gabriel Cohn

Gabriel Cohn

Chief Medical Officer

iECURE

3rd In Vivo Cell Engineering & Gene Editing Summit - Expert Speaker - Robert Mabry

Robert Mabry

Chief Scientific Officer

Orna Therapeutics

3rd In Vivo Cell Engineering & Gene Editing Summit - Expert Speaker - John Zuris

John Zuris

Director, Delivery & Editing Technologies

Editas Medicine

3rd In Vivo Cell Engineering & Gene Editing Summit - Expert Speaker - Dharini Shah

Dharini Shah

Senior Director, Research & Immunology

Sanofi

3rd In Vivo Cell Engineering & Gene Editing Summit - Expert Speaker - Michael Klinchinsky

Michael Klichinsky

Chief Scientific Officer

Carisma Therapeutics

Full Speaker Lineup

"The In Vivo Cell Engineering & Gene Editing Summit is a tremendous opportunity to engage with leaders in the field and discuss the latest advances"
Colin Exline, Head of Gene Editing, Primera Therapeutics

Back to Top